Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction.

Cardiovascular diabetology·2026
Same author

Diagnostic performance of combined biomarkers and phonocardiography vs. the 2024 ESC risk factor-weighted clinical likelihood model for detecting coronary artery disease.

European heart journal. Imaging methods and practice·2026
Same author

Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities.

European heart journal·2026
Same author

Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction.

Cardiovascular diabetology·2025
Same author

A multicentre observational study on landiolol use, efficacy, and safety in European patients with supraventricular arrhythmia (Landi-UP).

European heart journal. Acute cardiovascular care·2025
Same author

Importance of basic science and research training for the future generation of cardiologists.

European heart journal·2025
Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026
Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Platelet function variability and non-genetic causes.

Ioannis Tentzeris1, Jolanta Siller-Matula, Serdar Farhan

  • 13rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Montleartstrasse 37, Vienna, Austria.

Thrombosis and Haemostasis
|April 15, 2011
PubMed
Summary
This summary is machine-generated.

Dual antiplatelet therapy (DAPT) with clopidogrel is crucial for coronary artery disease. However, reduced platelet responsiveness, due to various factors, leads to severe cardiovascular events, necessitating further research.

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 2, 2026

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Dual antiplatelet therapy (DAPT) is a cornerstone in managing coronary artery disease (CAD), particularly post-acute coronary syndromes and interventions.
  • A significant subset of patients exhibit diminished therapeutic response to clopidogrel, a key antiplatelet agent.
  • This non-responsiveness is attributed to complex extrinsic and intrinsic mechanisms, impacting clinical outcomes.

Purpose of the Study:

  • To highlight the clinical significance of clopidogrel non-responsiveness in patients with coronary artery disease.
  • To identify both genetic and non-genetic factors contributing to variable responses to clopidogrel therapy.
  • To emphasize the need for further research to elucidate drug interactions and identify predictors of non-responsiveness.

Main Methods:

  • Review of existing data on dual antiplatelet therapy and clopidogrel responsiveness.
  • Identification of known genetic variability affecting antiplatelet therapy response.
  • Analysis of non-genetic factors including drug interactions and co-morbidities.

Main Results:

  • Clopidogrel non-responsiveness is linked to severe cardiovascular complications.
  • Non-genetic factors, including interactions with proton-pump inhibitors, statins, and co-morbidities like diabetes and renal failure, significantly influence clopidogrel efficacy.
  • Genetic variability also plays a role in patient response to antiplatelet therapy.

Conclusions:

  • Understanding and addressing clopidogrel non-responsiveness is critical for optimizing DAPT in CAD management.
  • Further large-scale clinical trials employing standardized methods are essential to pinpoint specific drug interactions and reliable predictors of clopidogrel non-responsiveness.
  • Personalized antiplatelet strategies may be required to mitigate risks associated with variable patient responses.